Related Experiment Video

Updated: Sep 26, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Marianne Abifadel1, Mathilde Varret, Jean-Pierre Rabès

  • 1INSERM U383, Hôpital Necker-Enfants Malades, AP-HP, Université Paris V, 149-161 rue de Sèvres, 75743 Paris Cedex 15, France.

Nature Genetics
|May 6, 2003
PubMed

Insights

Autosomal dominant hypercholesterolemia (ADH) is linked to mutations in LDLR or APOB genes. Researchers discovered two new mutations in the PCSK9 gene causing ADH, impacting cholesterol levels.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cardiovascular Disease Research

Background:

  • Autosomal dominant hypercholesterolemia (ADH) elevates low-density lipoprotein cholesterol, a significant coronary heart disease risk factor.
  • Mutations in LDLR and APOB genes are established causes of ADH.
  • A third genetic locus, HCHOLA3 at 1p32, was previously associated with ADH.

Purpose of the Study:

  • To identify the genetic basis of ADH linked to the HCHOLA3 locus.
  • To investigate the role of the PCSK9 gene in autosomal dominant hypercholesterolemia.

Main Methods:

  • Genetic linkage analysis to map the HCHOLA3 locus.
  • Mutation screening of the PCSK9 gene in patients with ADH.
  • Analysis of PCSK9 gene expression and function.

Main Results:

  • Two distinct mutations in the PCSK9 gene were identified in individuals with ADH.
  • PCSK9 encodes a novel human subtilase, NARC-1, highly expressed in the liver.
  • PCSK9 plays a role in regulating cholesterol homeostasis.

Conclusions:

  • Mutations in the PCSK9 gene are a newly identified cause of autosomal dominant hypercholesterolemia.
  • PCSK9 is implicated in cholesterol metabolism and cardiovascular disease risk.
  • Discovery of PCSK9 mutations expands the genetic understanding of hypercholesterolemia.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pedigree Analysis02:21

Pedigree Analysis

A pedigree is a diagram displaying a family’s history of a trait. Analyzing pedigrees can reveal (1) whether a trait is dominant or recessive, (2) the type of chromosome, autosomal or sex, a trait is linked to, (3) genotypes of family members, and (4) probabilities of phenotypes in future generations. For families with a history of autosomal or sex-linked diseases, this information can be crucial to family planning.Pedigrees Display Family HistoriesIn various plant and animal species,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Sex-linked Disorders02:28

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.Y chromosome mutations are called “Y-linked” and only affect males since they alone carry a copy of that chromosome. Mutations to the relatively small Y chromosome can impact male sexual function and secondary sex characteristics. Y-chromosome infertility is a disorder that affects sperm...
Mutations02:27

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously during DNA replication or be induced by environmental factors. Mutations can be characterized in several ways: by whether and how they alter the amino acid sequence of the protein, by the scale of the DNA affected, and by whether they affect somatic or germline cells.Consequences of Point Mutations at the Molecular LevelMutations that affect a single nucleotide are called point mutations. When point mutations...